Urine composition and stone formation during treatment with acetazolamide.
Twelve patients who formed renal stones during acetazolamide treatment for glaucoma were studied. Calcium phosphate was the dominating component in the stones. Long term treatment with acetazolamide decreased urinary citrate markedly, which will result in an increased ion-activity product of calcium phosphate and a decreased inhibiting property of urine on calcium phosphate crystallization. The treatment also increased urinary oxalate which together with a low citrate might increase the risk of calcium oxalate crystallization. However, an estimate of the ion-activity product of calcium oxalate in urine (AP [CaOx]-index) was unaffected by the treatment and calcium oxalate was a minor component of the stones.
Ahlstrand
C
C
Department of Urology, University Hospital, Linköping, Sweden.
Tiselius
H G
HG
D000086:Acetazolamide / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D002129:Calcium Oxalate / Q000652:urine; D002130:Calcium Phosphates / Q000652:urine*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007669:Kidney Calculi / Q000139:chemically induced* / Q000652:urine; D008297:Male; D008875:Middle Aged
D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D002129:Calcium Oxalate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous; D000086:Acetazolamide